Type 2 Diabetes Treatment in 2026: ADA Guidelines, GLP-1 Drugs, SGLT2 Inhibitors and Insulin

Evidence reviewed: 9 November 2026. Type 2 diabetes (T2D) is a chronic metabolic disease characterized by insulin resistance and progressive impairment of pancreatic beta-cell insulin secretion. Management aims to prevent hyperglycemia symptoms, hypoglycemia, cardiovascular events, chronic kidney disease, neuropathy and retinopathy while supporting quality of life. The American Diabetes Association (ADA) Standards of Care in Diabetes—2026 emphasize person-centered treatment, not an identical stepwise prescription for everyone. In people with atherosclerotic cardiovascular disease (ASCVD), heart failure or chronic kidney disease (CKD), selected SGLT2 inhibitors and/or GLP-1 receptor agonists with proven benefits are recommended irrespective of A1C and with or without metformin [1–4].

What causes type 2 diabetes?

Insulin released by pancreatic beta cells helps muscle, fat and liver regulate glucose availability. In T2D, tissues develop insulin resistance while insulin secretion gradually becomes insufficient for metabolic needs. Hepatic glucose production, altered incretin signaling, adipose inflammation, genetics and other metabolic pathways contribute [1,2].

Risk is influenced by family history, age, previous gestational diabetes, certain medical conditions, sleep, environmental factors and excess adiposity in some people. However, T2D also occurs in people without obesity. It is not simply caused by eating sugar or a failure of willpower, and treatment access should not depend on stigma or body size.

Symptoms and diagnosis

Possible symptoms include increased thirst, frequent urination, fatigue, blurred vision, unintentional weight loss or recurrent infections. Many people have few or no symptoms for years, making appropriate screening important. Diabetes can be diagnosed by standardized laboratory criteria [2].

Diagnostic test Diabetes threshold Important note
A1C 6.5% or higher (48 mmol/mol). Use standardized assay; anemia, hemoglobin variants and pregnancy can affect accuracy.
Fasting plasma glucose 126 mg/dL or higher (7.0 mmol/L). After appropriate fasting.
75-g oral glucose tolerance test 2-hour plasma glucose 200 mg/dL or higher (11.1 mmol/L). Specific testing conditions required.
Random plasma glucose 200 mg/dL or higher with classic symptoms or crisis. Otherwise, confirmatory testing generally required.

Diagnose and classify carefully. Adults with rapid weight loss, ketones, strongly positive autoantibodies or unexpectedly severe insulin deficiency may have autoimmune type 1 diabetes and need insulin immediately. In people without unequivocal hyperglycemia, confirmation with repeat or a second appropriate test is generally needed [2].

Individualized glucose and A1C targets

For many nonpregnant adults, the ADA suggests an A1C target of below 7%, but a lower or higher goal may be appropriate depending on age, hypoglycemia risk, comorbidities, life expectancy, treatment burden and personal priorities [3]. Some older adults with frailty or complex disease require less intensive glucose lowering to avoid harm.

Continuous glucose monitoring (CGM) can help selected people with T2D, particularly those using insulin and with a history of hypoglycemia, and the 2026 ADA standards place growing emphasis on access to diabetes technology. Time in range, hypoglycemia and day-to-day functioning may be more informative than A1C alone [2,3].

What lifestyle measures matter most?

Nutrition and activity plans should be individualized, sustainable and culturally appropriate. Useful approaches include higher-fiber vegetables, legumes, minimally processed whole grains, appropriate portions, healthy unsaturated fats and reduced sugar-sweetened beverages. Mediterranean and other evidence-based eating patterns can improve glycemia and cardiovascular risk when feasible [2].

Regular physical activity, including aerobic and strength exercise, improves insulin sensitivity and functional capacity. Sleep, stress, smoking cessation and treatment of hypertension or lipid disorders are also important. Lifestyle care is not a substitute for necessary cardioprotective or kidney-protective medication.

Why medication is no longer a simple “metformin first for everyone” ladder

Metformin remains useful and commonly prescribed, especially where affordability and glycemic efficacy are priorities. But the 2026 ADA Standards recommend choosing medicines according to ASCVD risk, heart failure, CKD, obesity and metabolic disease, A1C, adverse effects, cost and patient preferences, rather than requiring metformin before every other agent [1].

For someone with T2D and heart failure or CKD, a proven SGLT2 inhibitor may be recommended for clinical protection even when glucose is reasonably controlled. For people with established/high ASCVD risk, a proven GLP-1 RA and/or SGLT2 inhibitor can be indicated independent of A1C [1,4].

Drug classes and their mechanisms

Drug class Examples Main mechanism and role
Biguanide Metformin Reduces hepatic glucose production and improves insulin sensitivity; low hypoglycemia risk alone.
SGLT2 inhibitors Empagliflozin, dapagliflozin, canagliflozin Reduce renal glucose reabsorption; important cardiac and kidney benefits for selected patients.
GLP-1 receptor agonists Semaglutide, dulaglutide, liraglutide Increase glucose-dependent insulin release, reduce inappropriate glucagon and promote satiety; some have ASCVD/CKD benefit.
Dual GIP/GLP-1 agonist Tirzepatide Acts on two incretin receptors; substantial glucose and weight effects, with indication-specific outcomes.
DPP-4 inhibitors Sitagliptin, linagliptin Reduce incretin breakdown, modest glucose lowering, usually weight neutral.
Sulfonylureas Gliclazide, glimepiride Stimulate insulin secretion independently of glucose; hypoglycemia risk.
Thiazolidinedione Pioglitazone PPAR-gamma activation improves insulin sensitivity; may worsen fluid retention.
Insulin Basal and prandial preparations Essential for severe deficiency or selected treatment failure; requires hypoglycemia prevention.

Metformin: benefits and limits

Metformin is effective, generally affordable and typically does not cause hypoglycemia alone. Gastrointestinal effects such as nausea or diarrhea can improve with gradual titration or extended-release formulation. Long-term use can contribute to vitamin B12 deficiency, especially with anemia or neuropathy symptoms [1].

Metformin use depends on kidney function: it is generally contraindicated when eGFR is below 30 mL/min/1.73 m², with more cautious initiation and monitoring at reduced kidney function. Severe acute illness, hypoxia or dehydration can increase the rare risk of lactic acidosis; a patient should follow clinician-specific sick-day advice.

SGLT2 inhibitors: heart failure and kidney protection

SGLT2 inhibitors block glucose and sodium reabsorption in the kidney’s proximal tubule. They lower blood glucose and blood pressure modestly, but crucially reduce heart failure hospitalization and CKD progression in selected patients. The 2026 ADA CKD guidance recommends an SGLT2 inhibitor with demonstrated renal benefit in T2D and CKD, initiating at eGFR 20 mL/min/1.73 m² or higher when clinically appropriate [4].

Adverse effects include genital mycotic infections, volume depletion and rare euglycemic diabetic ketoacidosis (DKA). Patients should discuss holding the medicine for major surgery, prolonged fasting or significant acute illness according to product guidance. Do not confuse a normal glucose reading with an absence of DKA risk when nausea, abdominal pain or rapid breathing develops.

GLP-1 receptor agonists and tirzepatide

GLP-1 RAs stimulate insulin release when glucose is elevated, suppress inappropriate glucagon, slow gastric emptying to varying degrees and promote satiety. Some agents have demonstrated cardiovascular outcome and/or CKD benefit. Tirzepatide, a dual GIP/GLP-1 agonist, can have large effects on A1C and weight; selection depends on proven outcomes and local licensed indications [1,4].

Common adverse effects include nausea, vomiting, constipation or diarrhea. Clinicians should review gallbladder disease, pancreatitis symptoms, dehydration, severe gastroparesis, reproductive considerations and agent-specific thyroid-tumor warnings. Dose escalation should be gradual and tailored. More drug or faster escalation does not always mean safer or better treatment.

Do not combine a DPP-4 inhibitor with GLP-1-based therapy routinely

The 2026 ADA Standards explicitly advise against combining a DPP-4 inhibitor (such as sitagliptin) with a GLP-1 RA or dual GIP/GLP-1 agonist, because there is no meaningful additive glucose-lowering advantage [1]. In practice, the regimen should be reviewed when adding a new incretin medicine to avoid unnecessary expense and polypharmacy.

Sulfonylureas, TZDs and other options

Sulfonylureas are effective and inexpensive but increase the risk of hypoglycemia and weight gain, particularly in people with kidney impairment, inconsistent meals or advanced age. When other drugs are added, insulin and sulfonylurea doses may need adjustment to avoid low glucose [1].

Pioglitazone can improve insulin sensitivity and may have roles in selected patients, but causes weight gain and edema and may worsen heart failure; fracture risk and other clinical factors also matter. Alpha-glucosidase inhibitors and other agents may have narrow roles, but are not interchangeable with drugs selected for cardiovascular protection.

When does type 2 diabetes require insulin?

The ADA 2026 Standards advise considering insulin at any stage when there is symptomatic severe hyperglycemia, catabolic weight loss, a hyperglycemic crisis or very high A1C/glucose—for example A1C above 10% or glucose at least 300 mg/dL (16.7 mmol/L) [1].

In people without severe hyperglycemia or crisis, a GLP-1-based therapy is generally preferred over insulin for initial or add-on glucose lowering when appropriate. If insulin is needed, combining with a suitable GLP-1 agent may improve glucose and weight outcomes while reducing some insulin needs, subject to individualized dosing and access [1].

Heart failure: match drug choice to clinical risk

In T2D with heart failure—whether reduced or preserved ejection fraction—the 2026 ADA pharmacology recommendations support a proven SGLT2 inhibitor to reduce heart-failure hospitalizations, independent of A1C [1]. For people with obesity and symptomatic HFpEF, selected GLP-1 or dual GIP/GLP-1 agents with demonstrated benefit may also be appropriate [1].

Pioglitazone can cause fluid retention and may be unsuitable in symptomatic heart failure. A patient with dyspnea and edema requires appropriate cardiac evaluation, not merely a higher diabetes medication dose.

Chronic kidney disease: monitor eGFR and urine albumin

Check estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) as appropriate, usually at least annually in many adults with T2D. Albuminuria can signal kidney damage even with preserved eGFR [4].

Alongside SGLT2 inhibitors and some GLP-1 RAs, selected patients benefit from ACE inhibitors/ARBs for albuminuric hypertension, lipid treatment and other kidney-directed therapy. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, can benefit selected patients with T2D and albuminuric CKD but requires potassium and kidney monitoring.

Hypoglycemia: not every diabetes drug has the same risk

Insulin and sulfonylureas commonly cause clinically important hypoglycemia, especially with missed meals, exercise, illness or kidney impairment. Metformin, GLP-1 RAs and SGLT2 inhibitors have low hypoglycemia risk when used alone but can contribute to low readings when combined with insulin or sulfonylureas [1,3].

An awake person with a low glucose can often take about 15 g of rapid carbohydrate and recheck after 15 minutes, using an individualized plan. Severe confusion, seizure or unconsciousness requires emergency care and appropriate glucagon, not oral fluids or food in someone unable to swallow safely [3].

Hyperglycemic emergencies: DKA and HHS

Diabetic ketoacidosis (DKA) can occur in T2D as well as T1D, particularly during significant insulin deficiency or in selected people taking SGLT2 inhibitors. Symptoms include vomiting, abdominal pain, deep breathing, dehydration and confusion. Hyperosmolar hyperglycemic state (HHS) features profound hyperglycemia and dehydration, frequently with altered consciousness [3].

Both are emergencies. Avoid self-adjusting several medicines to treat persistent vomiting, rapid breathing or confusion; hospital assessment of electrolytes, ketones, acid-base status and hydration is needed.

Pregnancy and reproductive planning

The 2026 ADA pregnancy section states that insulin is preferred for management of T2D in pregnancy, with close preconception and antenatal support [5]. Some non-insulin agents are not recommended during pregnancy or require discontinuation well before conception. Patients planning pregnancy should review GLP-1 medicines, SGLT2 inhibitors, statins, blood-pressure drugs and other prescriptions with specialists.

Pregnancy glucose targets are more intensive and differently timed than nonpregnant goals; automatic use of the adult A1C target or a general treatment algorithm may be unsafe. Do not abruptly stop all diabetes treatment on discovering pregnancy—seek prompt coordinated review.

Children, older adults and frailty

Increasing numbers of young people develop T2D, often with high future metabolic burden. Treatment choices and approvals differ in children and adolescents. In older adults, frailty, cognitive function, kidney disease and medication complexity influence selection and A1C targets [2,3].

Where hypoglycemia risk is substantial, simplifying insulin or sulfonylurea regimens may be safer than striving for an unnecessarily tight target. Caregiver training and affordability matter in choosing a sustainable approach.

Preventing complications: coordinated follow-up

  • Review A1C or CGM patterns using individualized goals.
  • Monitor blood pressure, lipids and cardiovascular risk; discuss statin therapy as indicated.
  • Assess eGFR and UACR for kidney disease.
  • Arrange dilated retinal examinations at appropriate intervals.
  • Examine feet, neuropathy symptoms and vascular risk, with daily self-care where appropriate.
  • Review vaccinations, smoking, nutrition, exercise, sleep and mental-health burden.
  • Reconcile medicines and teach sick-day and hypoglycemia safety plans.

People with T2D benefit from a team including primary care, endocrinology, diabetes educators, pharmacists, dietitians and other specialists according to need. Evidence-based therapy should account for cost, medication supply and the patient’s ability to use the regimen correctly [1,2].

Case example: normal A1C but kidney disease

Consider a person with T2D and albuminuric CKD who has an A1C near their individualized goal while taking metformin. The 2026 ADA guidance still supports considering a proven SGLT2 inhibitor for kidney and cardiovascular protection if eligibility and safety criteria are met, irrespective of the A1C [1,4]. This illustrates why glucose alone cannot define adequate diabetes care.

Case example: severe symptomatic hyperglycemia

A person with polyuria, weight loss, dehydration and A1C 11% needs prompt evaluation for ketosis, insulin deficiency and dehydration. Insulin may be appropriate initially rather than waiting months for non-insulin drugs to work. Once stable, the long-term regimen should be reassessed according to the diabetes type and comorbidities [1,3].

Frequently asked questions

Is metformin mandatory before starting an SGLT2 inhibitor?

No. For selected T2D patients with ASCVD, heart failure or CKD, proven medications are recommended independent of A1C and with or without metformin [1].

Does every person with T2D need insulin?

No. But severe symptomatic hyperglycemia, ketosis or progressive insulin deficiency may make insulin essential.

Can GLP-1 drugs cause vomiting?

Yes. GI adverse effects are common, especially during dose increases, and severe or persistent symptoms need review.

Should sitagliptin be combined with semaglutide?

Generally no; the ADA discourages combining DPP-4 inhibitors with GLP-1-based therapy due to little additional benefit [1].

What A1C target is usual?

For many nonpregnant adults, below 7%, but goals are individualized to avoid harm [3].

Do SGLT2 medicines protect kidneys even when glucose is controlled?

Yes, in appropriately selected CKD patients with agent-specific evidence and eligibility [4].

Key takeaways

2026 type 2 diabetes care treats the whole cardiometabolic person, not just an A1C number. Match therapy to ASCVD, heart failure, kidney disease, weight goals, hypoglycemia risk and affordability. SGLT2 inhibitors and selected GLP-1 agents can protect heart and kidney outcomes independently of glycemia. Insulin remains important for severe hyperglycemia or deficiency, while nutrition, activity and regular complication screening support lifelong care.

References

  1. American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-s009.
  2. American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
  3. American Diabetes Association. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
  4. American Diabetes Association. Chronic kidney disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
  5. American Diabetes Association. Management of diabetes in pregnancy: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
  6. American Diabetes Association. Cardiovascular disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care. 2026.

Medical disclaimer: Educational material only. Diabetes medicines need individual prescriptions, kidney/liver assessment and interaction review. Do not start, stop or combine insulin, SGLT2 inhibitors or incretin agents without professional guidance. Severe hypoglycemia, vomiting with ketones, confusion, rapid breathing or hyperglycemic crisis requires emergency care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *